普瑞巴林靶向伤害感受机制预防鞭伤后慢性疼痛的可行性研究
本研究为一项双盲、安慰剂对照随机可行性研究方案,旨在评估普瑞巴林联合循证建议与安慰剂联合循证建议相比,对存在不良恢复风险的急性鞭伤相关疾病(WAD)患者的可行性和潜在有效性。计划招募30名(每组15名)18-65岁、Grade II WAD、伤后48小时内且当前疼痛至少为中度(NRS≥5/10)的患者,普瑞巴林从75 mg每日两次开始,耐受情况下滴定至300 mg每日两次,持续4周后减量1周。主要结局为随机化后3个月时的颈部疼痛强度。
要点
- 普瑞巴林从75 mg每日两次起始,耐受情况下滴定至300 mg每日两次,治疗4周后减量1周。
- 计划招募30名18-65岁Grade II WAD患者,伤后48小时内且NRS疼痛评分≥5/10。
- 主要结局为随机化后3个月时的颈部疼痛强度,采用标准方差分析比较组间差异。
核心结论
- 该可行性研究将检验试验程序的可行性及干预对结局的潜在效应,数据将用于设计样本量充分的正式试验。
研究设计与样本
- 双盲、安慰剂对照随机可行性研究,计划招募30名(每组15名)18-65岁Grade II WAD患者,伤后48小时内且当前疼痛至少为中度(NRS≥5/10),从澳大利亚昆士兰州公立医院急诊科招募。
主要发现
- 原文未报告研究结果,仅描述将检验试验程序可行性及干预对结局的潜在效应,主要结局为随机化后3个月颈部疼痛强度,采用标准方差分析比较组间差异。
关键数值与推荐
- 普瑞巴林从75 mg每日两次起始,耐受情况下滴定至300 mg每日两次,持续4周后减量1周。
- 纳入标准:18-65岁、Grade II WAD、伤后48小时内、当前疼痛NRS≥5/10。
临床怎么用
- 原文未报告临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whiplash-associated disorders (WAD) are an enormous and costly burden to Australian society. Up to 50% of people who experience a whiplash injury will never fully recover. Whiplash is resistant to treatment and no early management approach has yet been shown to prevent chronic pain. The early presence of central sensitization is associated with poor recovery. Pregabalin's effects on central sensitization indicate the potential to prevent or modulate these processes after whiplash injury and to improve health outcomes, but this has not been investigated. This paper describes the protocol for a feasibility study for a randomised controlled trial of pregabalin plus evidence-based advice compared to placebo plus evidence-based advice for individuals with acute whiplash injury who are at risk of poor recovery. METHODS: This double blind, placebo-controlled randomised feasibility study will examine the feasibility and potential effectiveness of pregabalin and evidence-based advice (intervention) compared to placebo and evidence-based advice (control) for individuals with acute whiplash injury at risk of poor recovery. Thirty participants (15 per group) aged 18-65 years with Grade II WAD, within 48 hours of injury and currently experiencing at least moderate pain (NRS: ≥ 5/10) will be recruited from Emergency Departments of public hospitals in Queensland, Australia. Pregabalin will be commenced at 75 mg bd and titrated up to 300 mg bd as tolerated for 4 weeks followed by 1 week of weaning. RESULTS: The feasibility of trial procedures will be tested, as well as the potential effect of the intervention on the outcomes. The primary outcome of neck pain intensity at 3 months from randomisation will be compared between the treatment groups using standard analysis of variance techniques. DISCUSSION: Feasibility and potential effectiveness data will inform an appropriately powered full trial, which if successful, will provide an effective and cost-effective intervention for a costly and treatment resistant condition. It will also have implications for the early management of other traumatic conditions beyond whiplash. TRIAL REGISTRATION: Clinical Trials Primary Registry: Australian and New Zealand Clinical Trials Registry. CLINICAL TRIAL REGISTRATION NUMBER: ACTRN12617000059369 . Date of Registration: 11/01/2017. Primary Trial Sponsor: The University of Queensland, Brisbane QLD 4072 Australia.
引用
- Nikles J, Keijzers G, Mitchell G, et al. Pregabalin versus placebo in targeting pro-nociceptive mechanisms to prevent chronic pain after whiplash injury in at-risk individuals - a feasibility study for a randomised controlled trial. Trials. 2018. PMID: 29343280. doi:10.1186/s13063-018-2450-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。